0.41 USD
▼-0.01-2.63%
盘后 0.43 0.00%
2026-11-20
市值
$107.04M
市盈率
—
EPS
-0.17
股息率
—
52 周区间
0.36 – 1.73
成交量
1.76M
Beta
0.23
目标价
2.67
52W 低 0.3652W 高 1.73
价格走势

公司简介

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia...